Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02651662 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
A Phase 1 study of Relapsed/Refractory Aggressive B-Cell Lymphoma, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
- 20
- Study locations
NCT02651662 is a Phase 1 study of Relapsed/Refractory Aggressive B-Cell Lymphoma that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 105 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT02651662, a Phase 1 study of Relapsed/Refractory Aggressive B-Cell Lymphoma, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810). The study is focused on patients who have relapse/refractory aggressive B-cell lymphoma. The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose regimen for the combination with odronextamab. This study is also looking at several other research questions, including: * What side effects may happen from taking the study drugs * How effective the study drugs are against the disease * How much study drug is in the blood at different times * Whether the body makes substances or protein called antibodies against the study drugs (that could make the drugs less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG cemiplimab
- DRUG odronextamab
Study Locations (20)
Other
- Uniklinikum Salzburg (LKH) Universitatsklinik fur Innere Medizin III - Salzburg
- Medical University Vienna - Vienna
- University Hospital Frankfurt - Frankfurt am Main
- Universitatsklinikum Jena - Jena
- Universitatsklinikum Schleswig-Holstein, Campus Kiel - Kiel
- Soroka - Beersheba
- Hadassah Medical Center - Jerusalem
- Chaim Sheba Medical Center - Ramat Gan
- Tel Aviv Sourasky Medical Center - Tel Aviv
- Pratia Onkologia Katowice - Katowice
- Copernicus Memorial Hospital - Lodz
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa - Warsaw
Massachusetts
- Dana Farber/Harvard Cancer Center - PO box 849168 - Boston
- Harvard Medical School - Beth Israel Deaconess Medical Center - Boston
Maryland
- Johns Hopkins University - Baltimore
Michigan
- Cancer & Hematology Centers of Western Michigan - Grand Rapids
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Malopolska
- Pratia MCM Krakow - Krakow
Pomeranian Voivodeship
- Uniwersyteckie Centrum Kliniczne - Gdansk
Cantabria
- Hospital Universitario Marques de Valdecilla - Santander
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2016-01-11 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02651662
The ClinicalTrials.gov registry entry for NCT02651662 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Aggressive B-Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which cemiplimab is the first listed.
NCT02651662 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Massachusetts, Maryland.
Frequently Asked Questions
What is clinical trial NCT02651662 about?
NCT02651662 is a clinical study titled "A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies". This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810). The study is focused on patients who have relapse/refractory aggressive B-cell lymphoma. The aim of the study is to see...
What is the current status of trial NCT02651662?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2016-01-11. Estimated completion is 2026-05-31.
What conditions does trial NCT02651662 study?
This clinical trial studies the following conditions: Relapsed/Refractory Aggressive B-Cell Lymphoma.
What interventions are being tested in trial NCT02651662?
The interventions under investigation include: cemiplimab (DRUG), odronextamab (DRUG).
Who is sponsoring clinical trial NCT02651662?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02651662 being conducted?
This trial has 20 study locations across Maryland, Massachusetts, Michigan, Ohio, Malopolska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.